Literature DB >> 4206451

A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

M H Wahdan, F Rizk, A M el-Akkad, A A el-Ghoroury, R Hablas, N I Girgis, A Amer, W Boctar, J E Sippel, E C Gotschlich, R Triau, W R Sanborn, B Cvjetanović.   

Abstract

A controlled field trial of a serogroup A meningococcal polysaccharide vaccine was conducted at three locations in Egypt during the winter cerebrospinal meningitis (CSM) season of 1971-72. The study population consisted of schoolchildren 6-15 years of age. No cases of serogroup A meningococcal CSM occurred in the group of students vaccinated with the test vaccine whereas 8 cases occurred in the control group vaccinated with tetanus toxoid, and 151 cases occurred in an unvaccinated contrast group. The case rate was significantly different between the test and control groups as well as between the test and contrast groups but was similar between the control and contrast groups. The previously demonstrated safety of the vaccine was confirmed. A significant serological response was elicited in the majority of the vaccinated students.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4206451      PMCID: PMC2483073     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Controlled field trials of prophylactics (with special reference to typhoid vaccines).

Authors:  B CVJETANOVIC
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1961

2.  Immunologic investigations of meningococcal disease. I. Group-specific Neisseria meningitidis antigens present in the serum of patients with fulminant meningococcemia.

Authors:  E A Edwards
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

3.  Meningitis as an epidemic disease.

Authors:  D C Kent
Journal:  J Egypt Public Health Assoc       Date:  1969

4.  Possibilities of application of complement fixation, indirect hemagglutination and fluorescent antibody tests to epidemiology of meningococcal infection.

Authors:  W R Sanborn; N A Vedros
Journal:  Health Lab Sci       Date:  1966-04

5.  [Comparative epidemiologic study of meningococcic cerebrospinal meningitis in temperate regions and in the meningitis belt in Africa. Attempt at synthesis].

Authors:  L Lapeyssonnie
Journal:  Med Trop (Mars)       Date:  1968 Nov-Dec

6.  [Sensitivity of meningococci of serotype A to sulfonamide drugs].

Authors:  M Vandekerkove; G Causse; L Lapeyssonnie; R Faucon
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

7.  Prevention of meningococcal disease by group C polysaccharide vaccine.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; H Schneider; C Harkins
Journal:  N Engl J Med       Date:  1970-02-19       Impact factor: 91.245

8.  Quantitative determination of the human immune response to immunization with meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; R Triau; K J Sparks
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

9.  Sulfadiazine-resistant group A Neisseria meningitidis.

Authors:  C E Alexander; W R Sanborn; G Cherriere; W H Crocker; P E Ewald; C R Kay
Journal:  Science       Date:  1968-09-06       Impact factor: 47.728

10.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  30 in total

Review 1.  Vaccine trials.

Authors:  C P Farrington; E Miller
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

Review 2.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 4.  Vaccines for prevention of meningococcal disease.

Authors:  C E Frasch
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

5.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Control of meningococcal epidemics.

Authors:  H Peltola
Journal:  Indian J Pediatr       Date:  1987 Mar-Apr       Impact factor: 1.967

7.  A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.

Authors:  M H Wahdan; S A Sallam; M N Hassan; A Abdel Gawad; A S Rakha; J E Sippel; R Hablas; W R Sanborn; N M Kassem; S M Riad; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

8.  Vaccine Development and Collaborations: Lessons from the History of the Meningococcal A Vaccine (1969-73).

Authors:  Baptiste Baylac-Paouly
Journal:  Med Hist       Date:  2019-10       Impact factor: 1.419

Review 9.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03

Review 10.  Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt.

Authors:  Lamyaa Shaban; Rania Siam
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-09-24       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.